The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I Grant Entitled “Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma”
Doylestown, PA. April 15, 2019 – FCCDC is pleased to announce that it has been awarded a Phase I STTR grant entitled “Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma” from the National Institute of Dental & Craniofacial Research of the National Institutes of Health (Prof. Robert Ricciardi, University of Pennsylvania, Principal Investigator).